A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.

A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.

View in: PubMed

subject areas

Angiogenesis Inhibitors
Humans
Indoles
Intravitreal Injections
Macular Degeneration
Neoplasm Recurrence, Local
Pyrazoles
Pyrimidines
Ranibizumab
Receptors, Vascular Endothelial Growth Factor
Treatment Outcome
Vascular Endothelial Growth Factor A
Wet Macular Degeneration

authors with profiles

Veeral Sheth